At 14:00 Central European Time (CET), Crucell's management willconduct a conference call, which will also be webcast. To participatein the conference call, please call one of the following telephonenumbers 10 minutes prior to the event:

+44 203 023 4471 for the UK; +1 646 843 4608 for the US; and +3120 794 8426 for the Netherlands

Following a presentation of the results, the lines will be opened fora question and answer session.

The live audio webcast can be accessed via the homepage of Crucell'swebsite at www.crucell.com and will be archived and available forreplay following the event.

About Crucell

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is aglobal biopharma company focused on research, development, productionand marketing of vaccines, proteins and antibodies that prevent andtreat primarily infectious diseases. Its vaccines are sold in publicand private markets worldwide. Crucell's core portfolio includes avaccine against hepatitis B, a fully-liquid vaccine against fiveimportant childhood diseases and a virosome-adjuvanted vaccineagainst influenza. Crucell also markets travel vaccines, such as theonly oral anti-typhoid vaccine, an oral cholera vaccine and the onlyaluminum-free hepatitis A vaccine on the market. The Company has abroad development pipeline, with several product candidates based onits unique PER.C6® production technology. The Company licenses itsPER.C6® technology and other technologies to the biopharmaceuticalindustry. Important partners and licensees include DSM Biologics,sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell isheadquartered in Leiden, the Netherlands, with subsidiaries inSwitzerland, Spain, Italy, Sweden, Korea and the US. The Companyemploys over a 1000 people. For more information, please visitwww.crucell.com.

Forward-looking statementsThis press release contains forward-looking statements that involveinherent risks and uncertainties. We have identified certainimportant factors that may cause actual results to differ materiallyfrom those contained in such forward-looking statements. Forinformation relating to these factors please refer to our Form 20-F,as filed with the U.S. Securities and Exchange Commission on May 7,2008, and the section entitled "Risk Factors". The Company preparesits financial statements under International Financial ReportingStandards (IFRS).

For further information please contact:

Crucell N.V.Oya YavuzDirector Corporate Communications & Investor RelationsTel. +31-(0)71-519 7064ir@crucell.comwww.crucell.com

This announcement was originally distributed by Hugin. The issuer issolely responsible for the content of this announcement.

Copyright © Hugin AS 2008. All rights reserved.